CellRapeutics™ In Vivo B Cell Engineering Service

In vivo immunotherapy currently confronts significant obstacles, including the intricate logistics, prohibitive costs, and scalability limitations inherent in ex vivo cell manufacturing. Creative Biolabs' CellRapeutics™ In Vivo B Cell Engineering Service enables the direct, systemic generation of persistent therapeutic cells within the patient. Our platform specializes in precisely reprogramming endogenous B cells into durable, self-renewing biologic factories. By leveraging proprietary viral vectors for targeted delivery and advanced synthetic gene circuits for controlled expression, we overcome traditional manufacturing bottlenecks to provide a scalable, long-lasting, and cost-effective solution for next-generation cell therapies.

Introduction

In vivo B cell engineering is an advanced technology that enables the in situ genomic modification of B cells within a living organism by delivering gene editing systems and therapeutic genes directly into the body. This approach bypasses the complex and costly ex vivo cell manufacturing process and leverages the inherent longevity and memory functions of B cells to achieve sustained and stable secretion of therapeutic proteins, such as broadly neutralizing antibodies. It thereby offers a more scalable and cost-effective therapeutic paradigm for persistent treatment needs in areas including infectious diseases, oncology, and autoimmune disorders.

Fig.1 In vivo engineered B cells for enhanced anti-HIV-1 neutralizing antibody production.¹

CellRapeutics™ In Vivo B Cell Engineering Service at Creative Biolabs

Creative Biolabs' CellRapeutics™ In Vivo B Cell Engineering Service directly reprogramming patients' own B cells in situ into durable, self-sustaining therapeutic protein factories, such as for bNAbs or custom biologics, we bypass costly ex vivo manufacturing. Our platform ensures sustained, targeted drug delivery, offering a precise and scalable solution for chronic infectious, oncological, and autoimmune disorders.

What we can offer

We offer a comprehensive in vivo B cell engineering platform that integrates targeted delivery, precision genome editing, programmable synthetic circuits, and optimized persistence strategies to enable the development of durable, self-sustaining cellular therapeutics.

Our Service Process

Required starting materials:

• Target Antigen/Epitope Information: Comprehensive sequence data, structure, and known binding affinities for the target of your therapeutic payload (e.g., bNAb or receptor antagonist).
• Therapeutic Payload Design: The genetic sequence of your desired output molecule (e.g., antibody heavy/light chains, synthetic circuit components, or fusion proteins) and its functional goals.
• Desired Delivery Vector Parameters: Any constraints or preferences regarding vector serotype (e.g., specific AAV variants for optimized B cell targeting) or promoter elements.

Key Steps:

Final Deliverables:

• Target Analysis and Vector Design Documentation: We provide comprehensive analytical documentation detailing the validated target and therapeutic payload strategy, along with the fully characterized vector constructs and plasmid samples, complete with sequence data and verification reports.
• Integrated Data Package: We deliver a robust in vitro functional validation report that includes B cell transduction efficiency, editing specificity, and off-target effect assessments, ensuring reliable and precise vector targeting.
• High-Quality Vector Bank: We supply a high-titer viral vector bank manufactured under stringent quality standards, accompanied by full purity, potency, and stability certifications.

Key Advantages

• Comprehensive, High-Throughput Screening: Simultaneous analysis of various cytokine and chemokine targets from a single, low-volume sample, providing the definitive, multi-dimensional view necessary to profile the full cytokine release syndrome cascade.
• Integrated Vector Design & Production: We provide a seamless workflow from therapeutic concept design to the production of high-titer, clinical-ready viral vectors, ensuring continuity and minimizing reliance on multiple external suppliers.
• Proprietary B Cell Targeting AAV Capsids: Our engineered AAV capsid libraries are optimized for superior systemic tropism and efficient in vivo targeting of B cell populations, enabling precise and effective delivery.

FAQ

Why Choose Us?

Creative Biolabs' In Vivo B Cell Development platform bypasses the complexity of ex vivo processing by enabling direct, in situ genetic engineering. We deliver durable, scalable therapies through precise, locus-specific editing of B cells, leveraging their intrinsic memory and longevity for sustained therapeutic secretion. Our approach ensures antigen-restricted expression, reduced immunogenicity, and a streamlined path to clinical translation.

Customer Reviews

"The design of the custom B cell specific promoter was a game-changer. It eliminated the off-target editing and payload expression we previously observed with non-specific vectors, providing the clean safety profile needed to progress our autoimmune therapeutic."— Ay Js, Director of Immunology Research.

"Using Creative Biolabs' In Vivo B Cell Engineering in our research has significantly improved the longevity of our antibody-based antiviral therapy. The sustained, high serum titers achieved in our NHP model were simply not possible with conventional protein injections or ex vivo CAR therapies."— Dr. Dd Hn.

"Creative Biolabs' commitment to in vivo AAV-based delivery simplified our supply chain immensely. We were able to move from a highly specialized, multi-site ex vivo protocol to a single, scalable intravenous administration method, dramatically reducing our projected cost."— P. Ls Sa, Ph.D.

How to Contact Us?

To harness the power of in vivo B cell engineering for simpler, more accessible therapies, partner with our experts. We offer comprehensive scientific support and project-specific consultation designed to accelerate your path to the clinic. Contact our team to initiate a dialogue and receive a detailed proposal.

Reference

1. Caijun et al. "B cell engineering in vivo: Accelerating induction of broadly neutralizing antibodies against HIV-1 infection." Signal transduction and targeted therapy vol. 8,1 13. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1038/s41392-022-01269-4.